Description

Hereditary factor 8 deficiency (hemophilia A) results in reduced levels of factor 8. This may be manifest as spontaneous hemorrhage with severe deficiency, or hemorrhage after trauma in its milder forms.


Inheritance:

(1) factor 8 is encoded on the X-chromosome (sex-linked)

(2) affects approximately 1 in 5,000-10,000 male births

(3) only rarely affects females

 

Clinical severity of disease correlates with the plasma factor 8 activity.

 

Level of Factor 8

Clinical Severity

> 50%

no bleeding

30 - 50%

may bleed after significant trauma or major surgery

10 - 30%

mild disease, with bleeding after trauma or surgery

2 - 10%

moderately severe disease; can have spontaneous hemorrhage or severe hemorrhage after minor trauma

< 2%

severe disease, with spontaneous hemorrhage into muscles or joints

 

Factor 8 Replacement Dosing

 

dose of factor 8 concentrate =

= (body weight in kilograms) * 0.5 * (increment in percent activity as whole number)

 

The dose can be administered:

(1) as intermittent intravenous infusion every 12 hours (half-life of infused factor 8)

(2) as a continuous infusion (approximately 2 units per hour per kg body weight will raise factor 8 level by 50% activity)

 

Product options include:

(1) cryoprecipitate (contains 90-100 units of factor 8 in approximately 20 mL)

(2) kogenate (recombinant factor 8 concentrate)

(3) helixate (recombinant factor 8 concentrate)

(4) recombinate (recombinant factor 8 concentrate)

(5) alphanate (solvent detergent treated concentrate from pooled human plasma)

(6) humate (pasteurized concentrate from pooled human plasma)

(7) koate (concentrate from pooled human plasma)

(8) monoclate (pasteurized concentrate from pooled human plasma)

 

Target Levels and Duration for Hemophilic Conditions

 

Clinical Condition

Target Plasma Level

Duration

hemarthroses

5 - 10%

2 - 3 days

hematuria

5 - 10%

2 - 3 days

hematomas

10 - 20%

4 - 7 days

moderately severe bleeding

40%

7 days

major surgery

> 60%

10-14 days

 

Anti-Factor 8 Inhibitors

 

Some patients with hemophilia A have circulating antibodies to factor 8, which act as inhibitors. Infusion of prothrombin complex concentrate can help to control hemorrhage related to circulating inhibitors.

 

dose of anti-inhibitor complex =

= (body weight in kilograms) * (number of units based on bleeding)

 

where:

• 25 units/kg are administered for mild bleeding, up to 100 units/kg for severe hemorrhaging

 

Contraindications: DIC

 

If bleeding has not been reduced at 6 hours, then the dose can be repeated.


To read more or access our algorithms and calculators, please log in or register.